Compare Micron Technology, Inc. (MU) vs Summit Therapeutics Inc (SMMT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Micron Technology, Inc. vs Summit Therapeutics Inc — how do they compare? Micron Technology, Inc. trades at $1,019.8 (market cap $1.13T), while Summit Therapeutics Inc trades at $17.52 (market cap $13.79B). The key difference: Micron Technology, Inc. is far larger — about 81.9× Summit Therapeutics Inc's market cap, and Micron Technology, Inc. pays a 0.05% dividend while Summit Therapeutics Inc pays none. Which is the better fit depends on your goals.
| MU | SMMT | |
|---|---|---|
Market Cap | $1.13T | $13.79B |
Sector | Technology | Health |
52-Week High | $1.21K | $26.38 |
52-Week Low | $140.00 | $12.43 |
Enterprise Value | $1.11T | $13.11B |
Dividend Yield | 0.05% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Micron Technology (MU) trades at $1,000.26, down 1.61% on the day, but remains in a bullish technical trend with strong analyst support. The stock has consistently beaten earnings estimates, with Q1 2026 EPS of $25.11 surpassing the $20.98 forecast. Fundamentals show robust growth, with 2025 revenue at $37.38 billion and net income margin of 55.91%. Positive sentiment is driven by AI-driven memory demand and projected 2026 revenue of $90.3 billion.
Outlook is bullish given memory supply constraints and AI tailwinds, but risks include cyclical industry volatility and high valuation multiples. The consensus price target is $1,540 with 82.9% of analysts rating it a buy. Investors should weigh strong cash flow growth against potential margin pressures if demand softens.
Summit Therapeutics (SMMT) trades at $17.28, down 1.85% on the day, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of $1.08 billion for 2025, negative ROE of -192.5%, and relies on financing cash flow for liquidity. Recent news highlights positive Phase III trial results for ivonescimab in lung and biliary tract cancers, driving investor optimism ahead of a key FDA decision in November 2026.
The outlook hinges on regulatory approval and commercial success of ivonescimab, with a consensus price target of $25.23 implying 46% upside. Risks include high cash burn, clinical trial uncertainties, and potential dilution from financing activities. Analyst sentiment is bullish (60.9% buy ratings), but the stock remains speculative due to its pre-revenue status and dependence on pipeline milestones.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Micron Technology, Inc.
Micron historically focused on designing and manufacturing DRAM for PCs. The firm then expanded into the NAND flash memory market. It increased its DRAM scale with the purchase of Elpida (completed in mid-2013) and Inotera (completed in December 2016). The firm's DRAM and NAND products tailored to PCs, data centers, smartphones, game consoles, automotives, and other computing devices.
Read more on MU →About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →
